Lower-Risk Myelodysplastic Syndromes (LR-MDS): Highlights from EHA 2024 - Episode 13
Perspectives of IMerge Study August 10, 2024
Guillermo Garcia-Manero, MD , Rami Komrokji, MD , Esther Natalie Oliva, MD , Amer Zeidan, MBBS, MHS , Thomas Cluzeau, MD, PhD
Medical professionals deliberate on patient selection criteria for second-line imetelstat treatment in lower-risk myelodysplastic syndromes, incorporating findings from the IMerge study into their considerations.
Please comment on which patients you would consider 2L imetelstat for patients with LR-MDS.Please provide a summary of the IMerge study, evaluating imetelstat in patients that R/R to ESAs in LR-MDS. (Platzbecker U, Santini V, Fenaux P, et al. Lancet. 2024;403(10423):249-260. ) Dr Komrokji: How does the latest follow up from the IMergestudy support the use of imetelstat in patients with LR-MDS?